KR20250044905A - 고리형 펩티드 유도체와 그 제조 방법 및 조성물 - Google Patents

고리형 펩티드 유도체와 그 제조 방법 및 조성물 Download PDF

Info

Publication number
KR20250044905A
KR20250044905A KR1020257006892A KR20257006892A KR20250044905A KR 20250044905 A KR20250044905 A KR 20250044905A KR 1020257006892 A KR1020257006892 A KR 1020257006892A KR 20257006892 A KR20257006892 A KR 20257006892A KR 20250044905 A KR20250044905 A KR 20250044905A
Authority
KR
South Korea
Prior art keywords
group
compound
mmol
hydrogen atom
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257006892A
Other languages
English (en)
Korean (ko)
Inventor
고헤이 마츠모토
유마 가리타
고스케 야스이
시치다이 다나베
다케시 쇼스
Original Assignee
다이이치 고교 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이치 고교 세이야쿠 가부시키가이샤 filed Critical 다이이치 고교 세이야쿠 가부시키가이샤
Publication of KR20250044905A publication Critical patent/KR20250044905A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257006892A 2022-08-04 2023-08-04 고리형 펩티드 유도체와 그 제조 방법 및 조성물 Pending KR20250044905A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022124810 2022-08-04
JPJP-P-2022-124810 2022-08-04
JP2022159060 2022-09-30
JPJP-P-2022-159060 2022-09-30
PCT/JP2023/028632 WO2024029630A1 (ja) 2022-08-04 2023-08-04 環状ペプチド誘導体とその製造方法および組成物

Publications (1)

Publication Number Publication Date
KR20250044905A true KR20250044905A (ko) 2025-04-01

Family

ID=89849507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257006892A Pending KR20250044905A (ko) 2022-08-04 2023-08-04 고리형 펩티드 유도체와 그 제조 방법 및 조성물

Country Status (12)

Country Link
US (1) US20260035407A1 (https=)
EP (1) EP4567042A1 (https=)
JP (1) JPWO2024029630A1 (https=)
KR (1) KR20250044905A (https=)
CN (1) CN119731193A (https=)
AU (1) AU2023317392A1 (https=)
CO (1) CO2025001948A2 (https=)
IL (1) IL318676A (https=)
MX (1) MX2025001373A (https=)
PE (1) PE20250797A1 (https=)
TW (1) TW202423948A (https=)
WO (1) WO2024029630A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
MX2025001373A (es) 2025-03-07
CN119731193A (zh) 2025-03-28
JPWO2024029630A1 (https=) 2024-02-08
IL318676A (en) 2025-03-01
PE20250797A1 (es) 2025-03-14
AU2023317392A9 (en) 2026-02-12
US20260035407A1 (en) 2026-02-05
TW202423948A (zh) 2024-06-16
WO2024029630A1 (ja) 2024-02-08
CO2025001948A2 (es) 2025-03-06
EP4567042A1 (en) 2025-06-11
AU2023317392A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
HU214820B (hu) Eljárás enkefalináz-és ACE-gátló 7-(acil-amino)-6-oxo-pirido[2,1-a][2] benzazepin-származékok és ezeket tartalmazó gyógyászati készítmények előállítására
JPH08508027A (ja) 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体
CA3113463A1 (en) Nitroxoline prodrug and use thereof
KR100635955B1 (ko) 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제
JP2026016715A (ja) 狂犬病治療のための環状アミド化合物およびその方法
JP3518606B2 (ja) Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
KR20250111317A (ko) 중추 신경계 손상 질환을 처치 또는 예방하기 위한 고리형 펩티드 유도체 조성물
KR20250044905A (ko) 고리형 펩티드 유도체와 그 제조 방법 및 조성물
KR20020016846A (ko) 4차 암모늄 유도체, 이의 제조 방법 및 약제학적 용도
EP4613283A1 (en) Cyclic peptide derivative composition for treating or preventing neuropathic pain and/or inflammatory pain
EP4595973A1 (en) Cyclic peptide derivative composition for treating or preventing eye disease
US6071968A (en) Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant
WO2025169980A1 (ja) テストステロンの産生／分泌を調節するための環状ペプチド誘導体組成物
WO2025169981A1 (ja) 脳機能を改善するための環状ペプチド誘導体組成物
US5225566A (en) Indazolanonyl derivative of benzopyran
JP2023084946A (ja) 生理活性を有する新規化合物
JP2023084944A (ja) 生理活性を有する新規化合物
US5137917A (en) Spergualin-related compound and use thereof
JP2022091476A (ja) 新規含窒素三環性骨格化合物およびその使用
JPH0820586A (ja) １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
CN119912460A (zh) 卟啉衍生物、其制备方法及其用于抑菌的用途
WO2024122113A1 (ja) 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application